Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Argos Therapeutics Inc.
DescriptionSecond-generation RNA-loaded autologous dendritic cell immunotherapy
Molecular Target Not applicable
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationRenal cancer
Indication DetailsFirst-line treatment of advanced renal cell carcinoma (RCC); Neoadjuvant treatment of localized renal cell carcinoma (RCC); Treat metastatic renal cell carcinoma (RCC)
Regulatory Designation U.S. - Fast Track (Treat metastatic renal cell carcinoma (RCC));
U.S. - Special Protocol Assessment (Treat metastatic renal cell carcinoma (RCC))
Partner Chongqing Lummy Pharmaceutical Co. Ltd.; Green Cross Corp.; Pharmstandard OJSC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today